Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.56 |
| ▸ | AR | P10275 | 4/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79517 | 0.81 | PGR (0.61) | PGRARNR3C1NR3C2 | |
| SCHEMBL1222341 | 0.76 | PGR (0.67) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL61925 | 0.73 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL29710912 | 0.73 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| SCHEMBL1223633 | 0.73 | PGR (0.69) | PGRARNR3C1NR3C2 | |
| SCHEMBL61743 | 0.72 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL4185522 | 0.71 | PGR (0.98) | PGRARNR3C1NR3C2 | |
| SCHEMBL1222818 | 0.68 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| SCHEMBL78394 | 0.68 | PGR (0.61) | PGRNR3C1 | |
| SCHEMBL7686696 | 0.67 | PGR (0.74) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1173433-B1 | CYANOPYRROLES AS PROGESTERONE RECEPTOR AGONISTS | WYETH CORP (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050256110-A1 | Cyanopyrroles | WYETH (US) | 2005-11-17 | — | — | US | claimed |
| US-6407101-B1 | PROGESTERONE RECEPTOR ANTAGONISTS; CONTRACEPTIVES, HORMONE REPLACEMENT THERAPY; BREAST AND PROSTATE CANCER TREATMENT; MENOPAUSE | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-18 | — | — | US | claimed |
| US-7846924-B2 | Cyanopyrroles | WYETH LLC (US) | 2010-12-07 | — | — | US | disclosed |
| US-6982261-B2 | Cyanopyrroles | WYETH (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050256110-A1 | Cyanopyrroles | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20030158182-A1 | A progesterone receptor antagonist for providing progestational therapy, treating cancer of breast, uterine, ovarian, endometrial, or prostate, providing contraceptives, hormone replacement therapy | WYETH | 2003-08-21 | — | — | US | disclosed |
| US-6562857-B2 | Progesterone receptor antagonist; inhibiting breast, uterine, ovarian, endometrial, or prostate cancer | WYETH | 2003-05-13 | — | — | US | disclosed |
| US-6407101-B1 | PROGESTERONE RECEPTOR ANTAGONISTS; CONTRACEPTIVES, HORMONE REPLACEMENT THERAPY; BREAST AND PROSTATE CANCER TREATMENT; MENOPAUSE | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-18 | — | — | US | disclosed |
| US-20020068735-A1 | Cyanopyrroles | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
| CN-1349531-A | Cyanopyrroles as progesterone receptor agonists | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256110-A1 | Cyanopyrroles | PGR, MC2R, THRB | PGR 1/4885AR 28/4885NR3C1 22/4885 |
| US-20020068735-A1 | Cyanopyrroles | PGR, NR3C2, GNRHR | PGR 1/4885AR 28/4885NR3C1 19/4885 |
| US-20030158182-A1 | A progesterone receptor antagonist for providing progestational therapy, treating cancer of breast, uterine, ovarian, endometrial, or prostate, providing contraceptives, hormone replacement therapy | PGR, GNRHR, AR | PGR 1/4885AR 3/4885NR3C1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.